Medical 3D illustration of a dividing cancer cell with a cell surface
Featured Story

Asian PDX Model Data Now Available

SXA 4219 10x H&ECancer drug development is moving at a rapid pace and obtaining favorably high success rates. With the prosperous growth of people and economics in Asian countries, access to cancer drugs has become an increased need.

As a consequence, approval of new anticancer agents is dependent on evaluating their safety and efficacy in the respective populations. In an effort to broaden our oncology portfolio, we have achieved a new milestone in close collaboration with our partner from NCC Japan, the group of Dr. Tadashi Kondo.

Dr. Kondo has generously contributed not only a substantial part of the PDX collection, but also his expertise specifically in rare cancers. We have a number of successful collaborations with academia and industry partners to provide a validated, robust, and high quality PDX platform to the scientific community.

Explore the Database

In the framework of our PDX model development strategy, we included 24 sarcoma models from the Kondo lab spanning a broad range of different subtypes, ranging from rhabdomyosarcoma to myxofibrosarcoma. The collaboration resulted in a platform offering 75 Asian models as part of our collection of over 1,100 tumor models easily accessible via the online database.